CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of CPI-613 when given together with
cytarabine and mitoxantrone hydrochloride in treating patients with relapsed or refractory
acute myeloid leukemia. Drugs used in chemotherapy, such as CPI-613, cytarabine and
mitoxantrone hydrochloride, work in different ways to stop the growth of cancer cells, either
by killing the cells or by stopping them from dividing. CPI-613 may help cytarabine and
mitoxantrone hydrochloride work better by making cancer cells more sensitive to the drugs